A regenerative medicine

company focused on

virility and fertility

Timothy WarbingtonChief Executive Officer

FEBRUARY 26, 2016

Creative Medical Technologies, Inc.

Forward Looking Statements

The following presentation contains certain “forward-looking statements”relating to such matters as anticipated financial performance, futurerevenues or earnings, business prospects, projected ventures, anticipatedmarker performance and similar matters.

The words “may”, “will”, “expect”, “anticipate”, “continue”, “estimate”,“project”, “intend” and similar expressions are intended to identifyforward-looking statements regarding events, conditions, and financialtrends that may affect future plans of operations, business strategy,operating results and financial position.

The expectations reflected in forward-looking statements involve risksand uncertainties; therefore, such expectations cannot guarantee futureresults, performance or achievements and actual results may varymaterially from projected results.

2

Patented, Proprietary Stem

Cell Therapy For Erectile

Dysfunction (ED) Using

The Patients Own Stem Cells

3

Outpatient Procedure

Not a drug

1 National Institute of Health (NIH) Consensus Conference. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90. (Reported patients seeking various treatments)

Erectile Dysfunction Marketplace

• 9,000,000 POTENTIAL UNSERVED PATIENTS

• Pumps & Prosthetics Only Option for those non-responsive to PDE5 inhibitors

• Invasive Surgery

• Penile tissue removed

• Risk of infection

• 24,000 procedures per year – 0.3% of Population

4

• 30 million US men have ED.1

• Growing ED population – Lifestyle & Longevity

• 30% do not respond to PDE5 inhibitors (Viagra, Cialis, Levitra) due to smooth muscle and blood vessel deterioration

CaverStem® Procedure

5

1Lin C-S et al. Advances in Andrology 2014.2 Song YS et al. International Journal of Impotence Research

2007;19:378.

• Intense academic interest –Because the technology works

• 20 Published papers in 2012-20131

• All studies reported improved erectile function

• Most reported improved muscle, endothelium and nerve tissue

Proof of Principle2

• Stem cells in an animal model of ED

• Proves stem cells translate into smooth

muscle tissue

Green - Transplanted stem cells in penis

Red - Stem cells expressing markers of smooth muscle cells

Yellow - Stem cells taking the morphology of smooth muscle cells in the penis

Time-Phase Penis Cell Extractions

Proven Science - Animal Research

6

Animal Research1

First-In-Human Pilot Study

1Ichim TE et al. Journal of Translational Medicine 2013 Jun 9:11:139

7

• Case study published in peer-reviewed journal1

• 35 year-old patient with ED

• Non-responsive to PDE5 inhibitors and injections ineffective

• Patient received Caverstem procedure

• 3 Months Later:

• Marked increase in duration and frequency of erections

• Ability to sustain erections until orgasm

• No treatment-associated adverse events

UCLA Clinical Trial

• Collaboration with Harbor-UCLA Medical Center and LABiomed

• Principal Investigator: Dr. Jacob Rajfer, MD, Chief of Urology at Harbor-UCLA Medical Center (emeritus)

• 40 Subject study using the Caverstem procedure

• Will establish Caverstem procedure as “Standard of Care”

• Milestones:

• Signed Study Contract: July 2015

• IRB Approval: September 2015

8

• Start Date: November 2015

• Study Complete: Dec. 2016

Business Model

• Issued Patent

• Validated Science & Credibility

• Exclusive Device/Kits Marketing Contract

• Revenue from Sale of Device/Kits to Urologists

• Competitive Advantage:

• First to market with “Standard of Care” procedure – 2017

• Full package offering – Protocol, Clinical Trial, Device/Kits, Training

• Patent is a barrier to entry

• Competitive Pricing better or equal to other offerings

• Sales Force In Place

9

• Handful of practices in the US

• No standard processes or protocols

• Illegal in some cases

• Examples:

• Priapus Shot® (P-Shot) – Illegal – Modified cells

• Smart Choice® Stem Cell Institute

• Phoenix Stem Cell Treatment Center

• DaSilvia Institute

Competition

10

Awareness

Sales &

Marketing

Press Releases During Study• Study Launch• 1st Patient In• Interim Results

Publication of Study Results• Journal of Urology• American Urology Association

AUA Conferences – Booth & Presentations• Annual – San Diego – May ‘16• Western – Hawaii – Oct ‘16• New York

Direct Sales to Urologists• Arteriocyte – 18 sales staff• Hire & train internal sales• Call on Urologist Practices

• New England• Central• Southeastern

Advertising – In Clinic• In-clinic hand-outs• Posters• White papers

Advertising – National• Print & Television• DTC• Long-Form Commercials

Physician Seminars & Training (inc. education credits)• Los Angeles• Texas

• New York• Florida

Commercialization Strategy

11

1 American Urological Association – 2014 State of the Urology Workforce

and Practice in the United States

2 # of Urologist owner/partners X % Urologist Adoption Rate X % Patients

Benefitting from Caverstem X Patient Adoption Rate

2014 US Urologist Population1

Total Number of US Urologists1: 11,601

# of Urologists Owners/Partners15,944 51% of Urologist Population

Est. # of Owned Practices 2,513 Individual & Partner Practices

# of Sales Staff 18

New Practice Sales Calls / Month 10

# of New Calls Per Year 2,160 86% of Practices Visited in 1 Year

Urologist adoption rate 35%

# of patients / urologist1 2,000

% of patients that benefit

from Caverstem 30%

Patient adoption rate 25%

Number of Potential Treatments2312,060

Sales Roll-Out

12

Timothy Warbington – Chairman/CEO

• Owned/operated multi-million dollar businesses over the past 25 years

• Health sciences, international trade, agriculture and transportation sectors.

Amit N. Patel, M.D., B.S., M.S., University of Utah Director & SAB Chairman

• Cardiothoracic surgeon

• Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah.

• Accomplished inventor and formulator of the Company’s Bionutraceutical® product lines.

Thomas Ichim, Ph.D. – President - Biotechnology Division

• Accomplished scientist

• CEO of Medistem, Inc. – Public biotech firm, successful exit March 2014

• Numerous executive positions in private and public biotechnology firms.

Donald Dickerson, MBA – Chief Financial / Operations Officer

• 25+ years senior management and accounting positions in public and private firms

• CFO of Medistem Inc. – Public biotech firm, successful exit March 2014

• Experience in the technology, manufacturing and health sciences sectors; JP Morgan, Dell, Boeing.

Annette Marleau, PhD - Chief Scientific Officer

• Director of Tumor Immunology at Aethlon Medical Inc

• Research Faculty at University of Nebraska Medical Center

• Fellow at Scripps Research Institute

Management Team

13

Summary

• First to Market with “Standard of Care” – 2017

• Competitively Priced Full Service Offering

• Sales Team In Place

14

• 9 Million Addressable

Patient Market

• Practically No Other

Options

• Issued Patent

• Validated Science &

Credibility